Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
The purpose of this clinical trial is to evaluate whether volatile organic compound (VOC) signatures detected in the breath of patients with cancer can serve as a potential screening tool for the early detection of cancer.
Checked against the public recordLast updated Jul 29, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Oklahoma
- Interventions being studied
- Device: Proton Transfer Reaction Mass Spectrometry Analysis
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age ≥ 18 at the time of consent. Male and female patients to be tested. * Capable of understanding written and/or spoken English language. * Able to provide informed consent. * Cancer of any type. * Newly diagnosed cancer and untreated or established diagnosis of cancer. For established cancer patients, no active anti-cancer treatment for more than one month (reasons for no treatment are such as relapse, progression of cancer, refractory, or intolerance to treatment etc.) Exclusion Criteria: * Under the age of 18. * Anticipated inability to complete breath sampling procedure. * Unable to provide informed consent. * Pregnant women * Active respiratory infection symptoms * Recent use of antibiotics * Difficulty in performing coached exhalation * Individuals who are unable to follow the instructions * Cancer patients who are on active treatment for cancer or have received cancer treatment within one month
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- OU Health Stephenson Cancer CenterOklahoma City, Oklahoma
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 29, 2026. Always confirm current availability with the study team.